^
Association details:
| Biomarker: | TNFRSF8 positive |
|---|---|
| Cancer: | Cutaneous T-cell Lymphoma |
| Drug: | gemcitabine (DNA synthesis inhibitor) + doxorubicin hydrochloride (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4453 Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-Cell Lymphomas
Published date:
11/02/2023
Excerpt:
Interestingly, 4 CD30+ CTCL patients were previously treated with brentuximab vedotin (BV). Of those, three (75%) had a response to GemDox, while only one achieved a response (PR) to BV. This demonstrates that GemDox is a potentially effective regimen in heavily refractory CD30+ CTCL patients that fail treatment with BV...GemDox produced an excellent ORR of 50%, with an impressive ORR of 82% in CTCL, suggesting this is an effective regimen for heavily pre-treated TCL patients.
